Effects of Ginkgo Biloba on Blood Biomarkers in Mild Cognitive Impairment

Inclusion Criteria: * Age 20 years or older * Clinical Dementia Rating (CDR) score of 0.5 * Patients clinically indicated for treatment with Ginkgo biloba extract Exclusion Criteria: * Current use of cholinesterase inhibitors such as donepezil, rivastigmine, or galantamine. * Refusal to provide informed consent. * Presence of neurological or psychiatric conditions other than Alzheimer's disease that may affect cognitive function. * Known hypersensitivity to Ginkgo biloba extract or any of its components. * Pregnant women. * Genetic conditions associated with lactose intolerance, including galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption. * Presence of bleeding disorders at screening, or requirement for continuous use of medications that may affect study drug efficacy (e.g., anticoagulants, antiplatelets, thrombolytics, peripheral vasodilators, PGE1 and its derivatives). * Any condition that, in the opinion of the investigator or study staff, makes the participant unsuitable for the study or unable to comply with study procedures.